Evidence map›Paper›PMID 34021910›Full record

ArticleImmunology2021

TLR2 dimer-specific ligands selectively activate protein kinase C isoforms in Leishmania infection.

Arkajyoti Mukherjee, Sayoni Roy, Ashok Patidar, Neelam Bodhale, Jagneswar Dandapat, Bhaskar Saha, Arup Sarkar

Open access · bronzeAbstract read
In one paragraph

Article in Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Anti-Pathogens (Basel, Switzerland) · 2024
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Arkajyoti MukherjeeTrident Academy of Creative Technology [TACT], Bhubaneswar, India.
Sayoni RoyNational Centre for Cell Science [NCCS], Pune, India.
Ashok PatidarNational Centre for Cell Science [NCCS], Pune, India.ORCID 0000-0003-0957-9680
Neelam BodhaleNational Centre for Cell Science [NCCS], Pune, India.
Jagneswar DandapatUtkal University, Bhubaneswar, India.ORCID 0000-0003-0928-1585
Bhaskar SahaTrident Academy of Creative Technology [TACT], Bhubaneswar, India.ORCID 0000-0002-5833-7912
Arup SarkarTrident Academy of Creative Technology [TACT], Bhubaneswar, India.ORCID 0000-0002-5030-2782
Creative Technology (Singapore) · SGNational Centre for Cell Science · INCalcutta Research Group · INUtkal University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Of the thirteen Toll-like receptors (TLRs) in mice, TLR2 has a unique ability of forming heterodimers with TLR1 and TLR6. Such associations lead to selective cellular signalling and cellular responses such as cytokine expression. One of the signalling intermediates is protein kinase C (PKC); of which, eight isoforms are expressed in macrophages. Leishmania-a protozoan parasite that resides and replicates in macrophages-selectively modulates PKC-α, PKC-β, PKC-δ and PKC-ζ isoforms in macrophages. As TLR2 plays significant roles in Leishmania infection, we examined whether these PKC isoforms play selective roles in TLR2 signalling and TLR2-induced anti-leishmanial functions. We observed that the TLR2 ligands-Pam

Indexed as

AnimalsCytokinesLeishmaniasis, CutaneousLigandsMacrophagesMiceMice, Inbred BALB CPhosphorylationProtein IsoformsProtein Kinase CSignal TransductionToll-Like Receptor 2CytokinesLigandsProtein IsoformsProtein Kinase CTlr2 protein, mouseToll-Like Receptor 2anti-leishmanial therapyLeishmaniaPKC inhibitorsprotein kinase C isoformsToll-like receptor

Identifiers

PMID34021910
PMCPMC8442242
OpenAlexW3161684523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.